An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer

Sponsor
Hoffmann-La Roche
Study ID
NCT01399190
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — BIOLOGICAL
    Bevacizumab administered according to prescribing information and normal clinical practice.
  • Capecitabine — BIOLOGICAL
    Capecitabine administered according to prescribing information and normal clinical practice.
  • Oxaliplatin — DRUG
    Capecitabine administered according to prescribing information and normal clinical practice.

Study Details

This prospective observational study will evaluate the efficacy and safety of bevacizumab in combination with capecitabine and oxaliplatin as first-line treatment in participants with colorectal cancer. Data will be collected from each participant until disease progression occurs (for up to 30 months).

Key Dates

First listed
Jul 21, 2011
Start date
Jul 31, 2011
Status verified
Aug 2016
Primary completion
Feb 28, 2014
Completion
Feb 28, 2014

Study Design

Enrollment
68 participants (actual)

Arms

  • Arm: Bevacizumab
    Participants will receive bevacizumab in combination with capecitabine and oxaliplatin.

Primary Outcome Measure

Progression-free Survival [ Time Frame: From randomization to progression or death during the study (up to approximately 30 months) ]

Related Studies